期刊文献+

原研伊马替尼转换国产伊马替尼治疗慢性髓性白血病慢性期的疗效和安全性

Efficacy and safety of conversion from original imatinib to domestic imat inib for chronic myelogenous leukemia
下载PDF
导出
摘要 目的:观察为使用原研伊马替尼的慢性髓性白血病慢性期(CML-CP)患者转换使用国产伊马替尼(商品名:格尼可)进行治疗的疗效和安全性。方法:回顾分析51例接受国产伊马替尼转换治疗的CML-CP患者(接受转换治疗前均获得稳定分子学反应)的临床资料。比较接受转换治疗前及接受转换治疗后第3个月、第6个月、第9个月、第12个月时其获得的分子学反应及不良反应的发生率,评估其对国产伊马替尼的接受度。结果:在接受转换治疗前后各随访时间点,这些患者获得分子学反应的等级相比,差异无统计学意义(P>0.05)。与接受转换治疗前相比,接受转换治疗后这些患者恶心症状的发生率较低,P=0.048;其他血液学不良反应及非血液学不良反应的发生率与接受转换治疗前相比,P>0.05。至随访期末,有48例(94.1%)患者表示愿意转换使用国产伊马替尼进行治疗。结论:为使用原研伊马替尼的CML-CP患者转换使用国产伊马替尼进行治疗的疗效良好,且安全性较高。 Objective:To observe the efficacy and safety of switching to domestic imatinib(trade name:Ginic)for chronic myeloid leukemia(CML-CP)patients who received original imatinib.Methods:The clinical data of 51 CML-CP patients who received domestic imatinib conversion therapy(all had stable molecular responses before conversion therapy)were reviewed.The incidence of molecular reactions and adverse reactions were compared before and after conversion therapy at 3,6,9 and 12 months,and the acceptance of domestic imatinib was evaluated.Results:There was no significant difference in the grade of molecular response before and after conversion therapy(P>0.05).These patients had a lower incidence of nausea after conversion therapy compared to before conversion therapy(P=0.048);The incidence of other hematological and non-hematological adverse reactions was compared with that before conversion therapy(P>0.05).At the end of follow-up,48 patients(94.1%)were willing to switch to domestic imatinib treatment.Conclusions:The conversion of domestic imatinib to treatment of CML-CP patients with original imatinib has good efficacy and high safety.
作者 杨文蓓 曾庆曙 倪婧 YANG Wenbei;ZENG Qingshu;NI Jing(The First Affiliated Hospital of Anhui Medical University,Hefei 230022)
出处 《当代医药论丛》 2021年第17期122-125,共4页
关键词 原研伊马替尼 国产伊马替尼 慢性髓性白血病 疗效 安全性 Yuanyan imatinib Domestic imatinib Chronic myelogenous leukemia Curative effect security
  • 相关文献

参考文献6

二级参考文献39

  • 1贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 2万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1283
  • 3O'Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in ontology: chronic myelogenous leukemia [J]. J Natl Compr Cane Netw, 2009, 7 (9) :984-1023.
  • 4Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS popu- lation- based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries [J]. Leukemia, 2015, 29(6):1336-1343.
  • 5Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015, 65( 1 ):5-29.
  • 6Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials [J]. Lancet Haematol, 2015, 2 (5): e1 86-193.
  • 7Kalmanti L, Saussele S, Lanseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV [J]. Leukemia, 2015, 29 (5):1123- 1132.
  • 8Jiang Q, Xu LP, Liu DH, et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic- phase chronic myelogenous leukemia [J]. Leukemia, 2013, 27 (12):2410- 2413.
  • 9Baccarani M, Deininger MW, Rosti G, et al. European Leukemi- aNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013, 122(6):872-884.
  • 10Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina [J]. Blood, 2015, 125( 18):2771-2778.

共引文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部